December 19, 2025
Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Nicholas A. Eitsert; A. Sasha Hoyt; Elliot C. Cook
In September and October, the PTAB cancelled 1,143 (79.82%) instituted claims across 70 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit. After review, 279 (19.48%) instituted claims survived.

For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 43 (61.43%) decisions, all instituted claims survived in 14 (20.00%) decisions, and a mixed outcome occurred in 13 (18.57%) decisions. A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Final Written Decision.

Through October 31, 2025, the PTAB has cumulatively granted 681 (15.46%) proposed substitute claims in motions to amend while denying 3,724 (84.54%) proposed substitute claims in IPRs.

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through October 31, 2025, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through October 31, 2025, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through October 31, 2025, are available here on the At the PTAB blog.
Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients. Stay tuned to the At the PTAB Blog for the latest updates, analysis, and statistics on all aspects of PTAB practice. Subscribe to receive notifications of new posts via email.
Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a
§ 325(d) EPR Denial
May 28, 2026
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.